Stem Cell Manufacturing Global Market Report 2024

The stem cell manufacturing market size has grown rapidly in recent years. It will grow from $15.78 billion in 2023 to $17.39 billion in 2024 at a compound annual growth rate (CAGR) of 10.2%. The growth observed during the historical period can be attributed to several factors, including advancements in biotechnology that expanded capabilities, increased research and development initiatives focused on stem cell technologies, the progression of clinical trials and their therapeutic applications, the establishment of regulatory frameworks governing stem cell use, and substantial investments in infrastructure supporting stem cell research and applications.

The stem cell manufacturing market size is expected to see rapid growth in the next few years. It will grow to $26.55 billion in 2028 at a compound annual growth rate (CAGR) of 11.2%. The anticipated growth in the forecast period is expected to be driven by increased funding and investments in stem cell research, the expanding scope of therapeutic applications, the emergence and advancement of cell-based therapies, a rise in the number of clinical trials and subsequent approvals, and the development of customized and patient-specific therapies. Key trends projected in the forecast period encompass a heightened focus on 3D bioprinting techniques within stem cell research, the continued expansion and utilization of induced pluripotent stem cells (iPSCs), integration of automation and robotics in stem cell manufacturing processes, efforts towards standardization and scalability in stem cell technologies, as well as advancements in bioreactor technology enhancing the cultivation and utilization of stem cells for various applications.

The rise in the geriatric population is set to drive the growth of the stem cell manufacturing market. The term 'geriatric population' pertains to individuals aged 65 and older who often experience various diseases due to compromised immunity and aging. The prevalence of chronic diseases increases with age, and stem cell manufacturing holds promise in combating these conditions. According to the United Nations Department of Economic and Social Affairs' September 2020 report, the global population aged 65 and above is projected to increase from 9.3% in 2020 to approximately 16.0% in 2050. Furthermore, a World Health Organization factsheet from October 2021 projects that there will be 1.4 billion individuals over the age of 60 worldwide by 2030, up from 1 billion in 2020. Consequently, the escalating geriatric population is a driving force behind the expansion of the stem cell manufacturing market.

The burgeoning biotechnology industry is expected to fuel the growth of the stem cell manufacturing market. The biotechnology sector, a rapidly expanding field, encompasses a wide range of products and services utilizing living organisms or their components to develop new technologies and solutions. Stem cell manufacturing, as a rapidly growing domain within biotechnology, has the potential to revolutionize the industry by creating novel therapies and treatments for various diseases. Notably, in March 2022, Airswift reported a 39.6% increase in capital invested in biotech companies, rising from $48 billion in 2020 to $67 billion in 2021. This substantial growth in the biotechnology industry is a key driver behind the expanding stem cell manufacturing market.

Technological advancement stands out as a crucial trend in the stem cell manufacturing market, with various stakeholders focusing on leveraging advanced technologies for sustainability. A noteworthy example is Cellino, a US-based biotech company specializing in stem cell manufacturing, which, in September 2021, integrated AI, machine learning, hardware, software, and lasers to enhance yields and reduce production expenses related to human cell production. This innovative approach eliminates human annotation and unpredictability by utilizing machine learning and AI, illustrating the importance of technological advancements in driving efficiency and progress within the stem cell manufacturing market.

Major companies within the stem cell manufacturing market are actively pursuing the development of innovative products, with a focus on GM-grade protein to attain a competitive advantage. GM-grade protein is a designation indicating that protein powders and related products meet specific standards for quality and safety. A noteworthy example is ACROBiosystems Inc., a US-based provider of recombinant proteins and critical reagents, which, in November 2023, introduced GM-grade DLL4 protein. This recombinant, soluble form of Delta-such as Ligand 4 (DLL4), a crucial signaling molecule in stem cell development and differentiation, signifies a significant milestone for advancing stem cell-based therapies. The availability of GMP-grade DLL4 ensures a high-quality, consistent, and scalable source of this essential protein, known for promoting the self-renewal and expansion of hematopoietic stem cells (HSCs). Its utilization in stem cell cultures enhances the growth and differentiation of HSCs, contributing to advancements in stem cell research and therapies.

In June 2021, Catalent, a New Jersey-based developer and producer of delivery methods for pharmaceuticals, biologics, and consumer health products, executed the acquisition of RheinCell Therapeutics GmbH for an undisclosed amount. This strategic move aimed to expand the creation of upcoming cell treatments and significantly enhance Catalent's capacity for large-scale production. RheinCell Therapeutics GmbH, a Germany-based manufacturer, specializes in GMP-grade human-induced pluripotent stem cells (iPSCs). The acquisition strengthens Catalent's position in the stem cell manufacturing market, emphasizing the importance of securing capabilities in producing high-quality stem cell materials for therapeutic applications.

Major companies operating in the stem cell manufacturing market report are Thermo Fisher Scientific Inc., Merck Millipore, Stemcell Technologies, Fujifilm Holdings Corporation, Takara Bio Group, Lonza Group AG, Sartorius AG, Bio-Rad Laboratories, Becton Dickinson and Company, Bio-Techne Corporation, Miltenyi Biotec, Terumo BCT Inc., Corning Inc., Eppendorf AG, ViaCyte Inc., Merck KGaA, Danaher Corporation, Vericel Corporation, American Cryostem Corporation, Cellgenix GMBH, Aspen Neuroscience Inc., Magenta Therapeutics Inc, Pluristem Therapeutics Inc., Takeda Pharmaceutical Company Limited, Daiichi Sankyo Chemical Pharma Co. Ltd., AbbVie Inc., 3D Biomatrix Inc., Worthington Biochemical Corporation, Bico Group, Vericel Corporation.

North America was the largest region in the stem cell manufacturing market in 2023. Europe was the second-largest region in the stem cell manufacturing market. The regions covered in the stem cell manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the stem cell manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary products within stem cell manufacturing comprise consumables, instruments, and stem cell lines. Consumables are utilized in growing new cells within culture media, contributing to applications in drug development, tissue culture, gene therapy, and toxicity testing. These consumables serve diverse purposes across research, clinical applications, and cell and tissue banking. They are used by a range of end-users including pharmaceutical and biotechnology companies, academic institutes, research laboratories, contract research organizations, hospitals and surgical centers, as well as cell and tissue banks.

The stem cell manufacturing market research report is one of a series of new reports that provides stem cell manufacturing market statistics, including stem cell manufacturing industry global market size, regional shares, competitors with a stem cell manufacturing market share, detailed stem cell manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the stem cell manufacturing industry. This stem cell manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.